Contrave naltrexone SR/bupropion SR: Additional Phase III data

FDA requested the assessment of CV health outcomes for Contrave in a complete response letter in 2011. Last September, FDA approved a resubmitted NDA for Contrave as an adjunct to diet and exercise for chronic weight management in adults

Read the full 392 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE